Client News

Posted: March 31, 2015, 9:58 pm
Posted: March 31, 2015, 9:58 pm
[AP] - A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: Ohr Pharmaceutical fell 32.1 percent to $7.74. Web.com Inc. fell 19.9 percent to $27.70. Aemetis Inc. fell 12.5 percent ...
Posted: March 31, 2015, 9:58 pm
[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...
Posted: March 31, 2015, 9:58 pm
[at noodls] - March 31, 2015 TORONTO - Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced the completion ...
Posted: March 31, 2015, 3:09 pm
[Business Wire] - Cynapsus Therapeutics Inc. , a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced the completi
Posted: March 31, 2015, 2:26 pm
Posted: March 31, 2015, 2:01 pm
Posted: March 31, 2015, 2:01 pm
[at noodls] - NEW YORK , March 31, 2015 /PRNewswire / -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: IMNP) announced today that it intends to expand its planned bullous pemphigoid ...
Posted: March 31, 2015, 12:39 pm
[PR Newswire] - NEW YORK, March 31, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (IMNP) announced today that it intends to expand its planned bullous pemphigoid (BP) clinical development for bertilimumab, a fully human monoclonal antibody targeting eotaxin-1. Bullous Pemphigoid is an orphan auto-immune blistering disease of the skin affecting approximately 60,000 patients in the US and Europe. As previously announced, Immune expects to start enrolling patients in a Phase II clinical trial in Israel to be treated during the second quarter of 2015. Additionally, following an International Medical Advisory Board meeting held in San Francisco immediately prior to the American Academy of Dermatology annual meeting, Immune has decided to expand its clinical program to include US centers in the Phase II BP development program.
Posted: March 31, 2015, 12:00 pm
[PR Newswire] - TEL AVIV, Israel, March 31, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization ...
Posted: March 31, 2015, 12:00 pm
Posted: March 31, 2015, 10:28 am
Posted: March 30, 2015, 9:57 pm
Posted: March 30, 2015, 9:57 pm
[at noodls] - Aurinia Pharmaceuticals Inc. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version.
Posted: March 30, 2015, 9:57 pm